Abstracts tagged "Biomarkers"

Abstract Number: 1903 • 2013 ACR/ARHP Annual Meeting
PIK3CD Overexpression In The Synovial Membrane Of Rheumatoid Arthritis Patients Is Associated With Response To Anti-TNF Therapy
Antonio Julià¹, Gabriela Ávila¹, Raquel Celis², Raimon Sanmarti³, Julio Ramirez⁴, Sara Marsal¹ and Juan D. Cañete³, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: The mechanisms by which Rheumatoid Arthritis (RA) patients do not respond to TNF blockade are still poorly characterized. The goal of this study is…
Abstract Number: 1345 • 2013 ACR/ARHP Annual Meeting
Retinal Vascular Calibre – a Novel Biomarker Of Inflammation and Treatment Response In Rheumatoid Arthritis
John HY Moi^1,2, Lauren AB Hodgson^3,4,5, Ian P Wicks^1,6,7, Tien Yin Wong^3,4,5,8 and Sharon Van Doornum^1,3,9, ¹Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ²Department of Medicine, The University of Melbourne, Melbourne, Australia, ³The University of Melbourne, Melbourne, Australia, ⁴Royal Victorian Eye and Ear Hospital, Melbourne, Australia, ⁵Centre for Eye Research Australia, Melbourne, Australia, ⁶Department of Medical Biology, University of Melbourne, Parkville, Australia, ⁷Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia, ⁸Singapore Eye Research Institute, Singapore, Singapore, ⁹Melbourne EpiCentre, The Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Retinal vascular calibre measurement is a non-invasive tool for assessing systemic and vascular health. Widened retinal venular calibre (RVC) is associated with systemic inflammation,…
Abstract Number: 444 • 2013 ACR/ARHP Annual Meeting
Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
M. C. Genovese¹, T. Kawabata², K. Soma², S. Menon², J.D. Clark³, J. Hodge⁴, L. Takiya⁴, R. Riese² and S. Krishnaswami⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). It has a short pharmacokinetic (PK) half-life of…
Abstract Number: 149 • 2013 ACR/ARHP Annual Meeting
Comparative Proteomic Analysis Of Neutrophils From Patients With Microscopic Polyangiitis and Granulomatosis With Polyangiitis
Teisuke Uchida¹, Kohei Nagai², Toshiyuki Sato³, Nobuko Iizuka³, Mitsumi Arito³, Yukiko Takakuwa⁴, Hiromasa Nakano⁴, Seido Ooka⁴, Manae Kurokawa³, Naoya Suematsu³, Kazuki Okamoto³, Shoichi Ozaki⁵ and Tomohiro Kato³, ¹Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, kawasaki, Japan, ²Department of Genetic Engineering, Faculty of Biology-Oriented Science and Technology, Kinki University, Wakayama, Japan, ³Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ⁴Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Both microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitis (AAV), in which neutrophils are thought to be involved in their…
Abstract Number: 2412 • 2013 ACR/ARHP Annual Meeting
Anti-CCP Antibodies and Increased Cartilage Turnover In Patients Developing Rheumatoid Arthritis
Carl Turesson¹, Christina Book², Ulf Bergström², Lennart Truedsson³, Lennart Jacobsson² and Tore Saxne⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ⁴Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Autoantibodies may be detected years before the onset of rheumatoid arthritis (RA). We have previously shown that levels of Cartilage oligomeric matrix protein (COMP),…
Abstract Number: 1869 • 2013 ACR/ARHP Annual Meeting
Serum Cytokine/Chemokine Profiles Are Useful For Evaluating Pathological Conditions Of Rheumatoid Arthritis and Diagnosing Anti-CCP Antibody-Negative Patients
Hitoshi Uga¹, Takahiro Okazawa¹, Yoshiaki Miyamoto¹, Takehiro Hasegawa¹, Jun Saegusa², Goh Tsuji³, Sho Sendo⁴, Akio Morinobu⁵, Shunichi Kumagai^6,7 and Hirokazu Kurata¹, ¹Sysmex Corporation, Kobe, Japan, ²Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan, ⁴Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, ⁵Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Center of rheumatic diseases, Shinko hospital, Kobe, Japan, ⁷Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: The diagnosis of anti-CCP antibody (ACPA) negative rheumatoid arthritis (RA) are known to be difficult and delayed as compared with ACPA-positive RA. This study…
Abstract Number: 1347 • 2013 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity Score For Rheumatoid Arthritis Predicts Radiographic Damage In The BeSt Study
I.M. Markusse¹, L. Dirven¹, M. van den Broek¹, K.H. Han², M.F. van Lieshout³, N. Riyazi⁴, R.J. Bolce⁵, E.H. Sasso⁵, P.J.S.M. Kerstens⁶, W.F. Lems⁷, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Spaarne Hospital, Hoofddorp, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: To determine whether a multi-biomarker disease activity (MBDA) score could predict radiographic damage progression in patients with rheumatoid arthritis (RA). Methods: The BeSt study…
Abstract Number: 458 • 2013 ACR/ARHP Annual Meeting
High Levels Of Natural Killer CELLS ARE Associated With Response To Tocilizumab In Patients With Severe Rheumatoid Arthritis
Claire I. Daien^1,2, Sarah Gailhac³, Rachel Audo¹, Thibault Mura⁴, Michael Hahne¹, Bernard Combe⁵ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Igmm UMR3555, CNRS, Montpellier, France, ⁴CIC, Hopital Gui De Chauliac, Montpellier, France, ⁵Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Inhibition of interleukin 6 (IL-6) receptor with tocilizumab (TCZ) is effective for rheumatoid arthritis (RA). However, the effect of TCZ on lymphocytes remains poorly…
Abstract Number: 156 • 2013 ACR/ARHP Annual Meeting
Cartilage Peptide Profiling: Identifying Novel OA Biomarkers For Early Disease Detection
Valentina Calamia¹, Lucía Lourido¹, Diego López¹, Jesus Mateos¹, Patricia Fernández-Puente¹, Carolina Fernández-Costa², Beatriz Rocha², Cristina Ruiz-Romero³ and Francisco J. Blanco¹, ¹Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain, ²Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ³Grupo de Proteomica-PBR2-ProteoRed/ISCIII Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006 A Coruña, Spain, A Coruña, Spain
Background/Purpose: Cartilage secretome contains a complex matrix of proteolytically derived peptides that may provide useful information of the biological events occurring in the articular joint…
Abstract Number: 2391 • 2013 ACR/ARHP Annual Meeting
Pathogenic Pro-Inflammatory Cytokine Production Induced By Synovial Fluid From RA Patients Is Related To Levels Of Endogenous TLR4 Ligands and Is Blocked By a Novel Therapeutic Anti-Human TLR4 Monoclonal Antibody, NI-0101
Limin Shang¹, Greg Elson¹, Jeremy Sokolove², Iain B. McInnes³, James Reilly⁴, Eric Hatterer¹, Marie Kosco-Vilbois⁵, Walter Ferlin⁵, Emmanuel Monnet⁵ and Cristina de Min⁶, ¹NovImmune S.A., Plan-Les-Ouates, Geneva, Switzerland, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵NovImmune S.A., Geneva, Switzerland, ⁶Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland
Background/Purpose: Deregulation of Toll-Like Receptor 4 (TLR4) signaling is thought to play a role in the pathogenesis of certain autoimmune diseases. In rheumatoid arthritis (RA),…
Abstract Number: 1876 • 2013 ACR/ARHP Annual Meeting
Potential Chondrogenic Biomarkers For Cell-Based Therapy Monitoring In Osteoarthritis
Beatriz Rocha¹, Valentina Calamia², Vanessa Casas³, Lucia Lourido², Carolina Fernandez-Costa², Patricia Fernandez-Puente², Jesus Mateos², Montserrat Carrascal³, Francisco J. Blanco² and Cristina Ruiz-Romero^1,4, ¹Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ²Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Laboratorio de Proteómica CSIC/UAB, Barcelona, Spain, ⁴CIBER-BBN, INIBIC-CHUAC, A Coruña, Spain
Background/Purpose: Chondrogenesis occurs as a result of mesenchymal stem cells (MSCs) condensation and chondroprogenitor cell differentiation. Following chondrogenesis, the chondrocytes remain as resting cells to…
Abstract Number: 1321 • 2013 ACR/ARHP Annual Meeting
Vasoactive Intestinal Peptide Serum Levels As a Marker Of Prognosis In Rheumatoid Arthritis
Rosario Garcia-Vicuña¹, Ana M. Ortiz², Iria Valino-Seoane³, Amalia Lamana¹, Javier Leceta³, Yasmina Juarranz³, Isidoro González-Alvaro², Rosa P Gomariz³ and Carmen Martinez-Mora⁴, ¹Rheumatology, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain, ²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ³Cellular Biology, School of Biology. Universidad Complutense de Madrid, Madrid, Spain, ⁴Cellular Biology, School of Medicine. Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The current shift to earlier treatment of Rheumatoid Arthritis (RA) has a major unmet need in the availability of biomarkers to identify patients requiring more…
Abstract Number: 381 • 2013 ACR/ARHP Annual Meeting
Coronary Endothelial Dysfunction Directly Measured By N13 Positron Emission Tomography (PET) Is Detected In Established Rheumatoid Arthritis (RA), But Not Early RA
OM Troum¹, OL Pimienta¹, B Hidalgo² and WA Hsueh³, ¹Keck School of Medicine, University of Southern California, Los Angeles, CA, ²Biostatistics, University of Alabama, Birmingham, AL, ³Medicine, Weill Cornell Medical College, Houston, TX
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular (CV) disease. The endothelium is a key regulator of vascular function. Subclinical CV disease and…
Abstract Number: 2374 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects
Jeffrey Voss¹, Candace Graff², Annette Schwartz³, Deborah Hyland⁴, Maria Argiriadi⁴, Heidi Camp⁵, Lori Dowding⁴, Michael Friedman⁴, Kristine Frank⁵, Jonathon George⁴, Eric Goedken⁴, Gloria Lo Schiavo⁴, Michael Morytko⁴, Robert o'Brien⁴, Robert Padley⁶, Matthew Rosebraugh⁵, Michael Rozema⁵, Kent Stewart⁵, Grier Wallace⁴, Neil Wishart⁴, Anwar Murtaza⁷ and Lisa Olson³, ¹Immunology, AbbVie Pharmaceuticals, Worcester, MA, ²Drug Metabolism and Pharmacokinetics, Abbvie Pharmaceuticals, worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Abbvie Pharmaceuticals, worcester, MA, ⁵abbvie pharmaceuticals, north chicago, IL, ⁶AbbVie, Inc, North Chicago, IL, ⁷Broad Institute, Cambridge, MA
Background/Purpose: Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can arrest disease progression. Despite numerous treatment options there…
Abstract Number: 1878 • 2013 ACR/ARHP Annual Meeting
Proteomics Analysis Of Cartilage Secretome: A Powerful Tool For The Discovery Of OA Biomarkers
Lucía Lourido¹, Valentina Calamia¹, Patricia Fernández-Puente¹, Jesus Mateos¹, Beatriz Rocha², Carolina Fernández-Costa², Francisco J. Blanco¹ and Cristina Ruiz-Romero³, ¹Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain, ²Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ³Grupo de Proteomica-PBR2-ProteoRed/ISCIII Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006 A Coruña, Spain, A Coruña, Spain
Background/Purpose: Osteoarthritis (OA) is characterized by the progressive loss of cartilage structural extracellular matrix (ECM) components, mainly collagenous and non-collagenous proteins. The release of these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].